Skip to main content
Premium Trial:

Request an Annual Quote

NorDiag Extends License to Exact Sciences' Long-DNA Biomarker Tech

NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag. 
 
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
 
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.
 
NorDiag will pay a licensing fee and royalties for the right to use the technology, Exact said. Financial details were not disclosed.
 
Exact Sciences said that when the DIA marker is detected in stool samples, “multiple studies have shown both high sensitivity and specificity for the presence of colorectal cancer.”
 
Exact Sciences CEO Don Hardison said his company looks forward to entering other collaborations with NorDiag “to explore ways in which we may further leverage each other’s strengths, while continuing to advance stool-based DNA testing worldwide.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.